USANA Health Sciences Files 8-K on Financials
Ticker: USNA · Form: 8-K · Filed: Oct 22, 2024 · CIK: 896264
| Field | Detail |
|---|---|
| Company | Usana Health Sciences Inc (USNA) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: USNA
TL;DR
USANA filed an 8-K today, expect financial updates soon.
AI Summary
On October 22, 2024, USANA Health Sciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or operational details were provided in the excerpt.
Why It Matters
This 8-K filing indicates that USANA Health Sciences is providing updates on its financial performance and operational status to the SEC and the public.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for financial disclosures and does not indicate any immediate adverse events.
Key Players & Entities
- USANA HEALTH SCIENCES, INC. (company) — Registrant
- October 22, 2024 (date) — Date of Report
- Utah (location) — State of Incorporation
- Salt Lake City (location) — Principal Executive Offices City
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on USANA Health Sciences, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements.
When was this 8-K report filed?
This 8-K report was filed on October 22, 2024.
What is the exact name of the registrant?
The exact name of the registrant is USANA HEALTH SCIENCES, INC.
In which state was USANA Health Sciences, Inc. incorporated?
USANA Health Sciences, Inc. was incorporated in Utah.
What is the address of USANA Health Sciences, Inc.'s principal executive offices?
The address of USANA Health Sciences, Inc.'s principal executive offices is 3838 West Parkway Boulevard, Salt Lake City, Utah 84120.
Filing Stats: 701 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-22 16:12:14
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share USNA New York Stock
Filing Documents
- usna-20241022.htm (8-K) — 28KB
- q32024earningsreleaseex991.htm (EX-99.1) — 156KB
- q32024managementcommentary.htm (EX-99.2) — 66KB
- usanacorplogoresizeda.jpg (GRAPHIC) — 9KB
- 0001628280-24-043281.txt ( ) — 404KB
- usna-20241022.xsd (EX-101.SCH) — 2KB
- usna-20241022_lab.xml (EX-101.LAB) — 21KB
- usna-20241022_pre.xml (EX-101.PRE) — 12KB
- usna-20241022_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 22, 2024, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing its financial results for the third quarter ended September 28, 2024. The release also announced that the Company will post a document titled "Management Commentary" on the Company's website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company's management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company's corporate website, www.usana.com. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by USANA Health Sciences, Inc. dated October 22 , 2024 (furnished herewith). 99.2 Management Commentary provided by USANA Health Sciences, Inc. dated October 2 2 , 2024 (furnished herewith). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. USANA HEALTH SCIENCES, INC. By: /s/ G. Douglas Hekking G. Douglas Hekking, Chief Financial Officer Date: October 22, 2024